← Leaderboards
Raghuraman Kannan
University Of Missouri-Columbia
$5,372,272
Attributed
$5,372,272
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,372,272 · 3
By mechanism
R01$4,923,772 · 2
R21$448,500 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Jered C Garrison$6,180,863
- Kattesh V Katti$3,115,330
- Ov D Slayden$15,947,398
- Wynn A Volkert$12,525,320
- Mark A. Daniels$297,679
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoIn VitroTumorXenograft ProcedureLeadCellsNanoparticleSurvival RateCancer PatientDoseAnimal ModelClinical TrialsLibrariesExhibitsInhibitor TherapyFutureGelatinKnock-DownDrug KineticsDrug ResistanceAntibodiesCancer TherapyEpidermal Growth Factor ReceptorBiodistribution
Grant awards (11)
Engineering Dual-Targeted Nanoplatforms to Effectively Treat NSCLC.$629,729
R01 · FY2025 · EB · contact PI
Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC$563,952
R01 · FY2025 · CA · contact PI
Engineering Dual-Targeted Nanoplatforms to Effectively Treat NSCLC.$634,874
R01 · FY2024 · EB · contact PI
Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC$545,975
R01 · FY2024 · CA · contact PI
Engineering Dual-Targeted Nanoplatforms to Effectively Treat NSCLC.$661,001
R01 · FY2023 · EB · contact PI
Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC$578,421
R01 · FY2023 · CA · contact PI
Engineering Dual-Targeted Nanoplatforms to Effectively Treat NSCLC.$687,752
R01 · FY2022 · EB · contact PI
Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC$622,068
R01 · FY2022 · CA · contact PI
Targeted Gold Nanoparticle-Bioconjugates for Imaging Breast Cancer$149,500
R21 · FY2009 · CA · contact PI
Targeted Gold Nanoparticle-Bioconjugates for Imaging Breast Cancer$149,500
R21 · FY2008 · CA · contact PI
Targeted Gold Nanoparticle-Bioconjugates for Imaging Breast Cancer$149,500
R21 · FY2007 · CA · contact PI